Drugs.com New Drug ApplicationsOriginal article
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
NDA FilingmezigdomidecarfilzomibPositive
AI Analysis
Summary
Bristol Myers Squibb announced FDA acceptance of its New Drug Application for mezigdomide in combination with carfilzomib for patients with relapsed or refractory multiple myeloma. This represents a positive regulatory milestone advancing the company's oncology pipeline.
Outcome Details
FDA accepted New Drug Application for mezigdomide in combination with carfilzomib
Importance:7/10
Sentiment:
0.70
FDANDAmultiple myelomadrug combinationregulatory milestone
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on July 13, 2026 2:07 AM